A
NTLA icon

AlphaQuest’s Intellia Therapeutics NTLA Stock Holding History

AlphaQuest’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-27,588
Closed -$248K – 1370
2025
Q4 		$248K Buy
27,588
+11,712
+74% +$161K 0.01% 1339
2025
Q3 		$274K Sell
15,876
-6,339
-29% -$78.1K 0.02% 1220
2025
Q2 		$208K Sell
22,215
-29,619
-57% -$243K 0.02% 1101
2025
Q1 		$369K Buy
51,834
+31,096
+150% +$314K 0.04% 672
2024
Q4 		$242K Buy
20,738
+990
+5% +$15.4K 0.03% 792
2024
Q3 		$406K Buy
19,748
+12,734
+182% +$294K 0.04% 754
2024
Q2 		$157K Sell
7,014
-2,793
-28% -$66.5K 0.02% 824
2024
Q1 		$270K Sell
9,807
-609
-6% -$16.9K 0.05% 555
2023
Q4 		$318K Buy
+10,416
New +$299K 0.07% 495

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

AlphaQuest's NTLA Position: Q1 2026 in Review

AlphaQuest sold out of Intellia Therapeutics (NTLA) in Q1 2026, closing a stake of 27,588 shares — an estimated $248K sold.

AlphaQuest first reported a position in NTLA in Q4 2023 and held it in 9 quarters. The position peaked at $406K in Q3 2024. 304 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • AlphaQuest reported no remaining Intellia Therapeutics position as of Q1 2026 after selling out during the quarter.
  • AlphaQuest sold 27,588 Intellia Therapeutics shares in Q1 2026, an estimated $248K.
  • AlphaQuest first reported a position in Intellia Therapeutics in Q4 2023 and held it in 9 quarters.
  • AlphaQuest's Intellia Therapeutics position peaked at $406K in Q3 2024.
  • 304 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on AlphaQuest's 13F filing for Q1 2026.